Avexia

Avexia’s May 2026 mix concentrated in Topical at 50.22% share with a year-over-year decline of 27.57% and a month-over-month decline of 17.47%, while Capsules held 21.32% share with year-over-year down 40.20% and month-over-month down 4.94%. Concentrates represented 18.29% share with a year-over-year drop of 63.02% and a month-over-month decrease of 21.03%, contrasted with Tincture & Sublingual at 10.17% share posting a year-over-year decline of 30.60% but a month-over-month increase of 7.25%. Average price fell 6.75% year over year to $27.84, and Topical’s higher average price of 32.94 suggests mix pressure as the fastest month-over-month contraction sat in Concentrates at 21.03% and Topical at 17.47%. Taken together with a May 2026 brand sales change of -40.87% year over year and a 24‑month change of -55.57%, the pattern implies near-term volume contraction is being driven more by category-level retrenchment in Topical and Concentrates than by price, with Tincture & Sublingual offering the only near-month offset.

Positioning-wise, Avexia is anchored in Topical where it holds rank 1 in Illinois, yet the 17.47% month-over-month decline in that anchor category alongside a 21.03% month-over-month drop in Concentrates signals overexposure to the categories exerting the steepest near-term drag. The 7.25% month-over-month lift in Tincture & Sublingual and the 4.94% month-over-month decline in Capsules indicate that shifting incremental effort toward Tincture & Sublingual could buffer volatility without materially diluting the 50.22% Topical share. The combination of a 6.75% year-over-year price decrease and a 30.60% year-over-year decline in Tincture & Sublingual suggests elasticity headroom, implying that maintaining Topical leadership while reallocating growth tests into Tincture & Sublingual may stabilize the overall trajectory more effectively than leaning on Concentrates recovery.